Together, their complementary mechanisms have generated significant scientific interest
Looking ahead, the market is projected to reach approximately USD 268.37 billion by 2034, growing steadily at a strong CAGR of 17.5% from 2025 to 2034
No signs of AI-generated content
It doesnt mean that they dont have a few side effects, but they say that the trade-off is very worthwhile. Moore expects newer generations of GLP-1 medications to continue improving
These drugs slow digestion, help control blood sugar, and reduce appetite
It is no secret that GLP-1 agonist medications like semaglutide Ozempic, Wegovy have demonstrated both effectiveness and popularity for treating obesity, he told us